Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality

Abstract We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large population-based dataset. 388,760 men who participated in national health screening program in Korea during 2002–2003 were observed from 2004 to 2013. Haza...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hye Yeon Koo, Su-Min Jeong, Mi Hee Cho, Sohyun Chun, Dong Wook Shin, Jinsung Park
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ec98b4039ee4428da42d76d143f81a9f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ec98b4039ee4428da42d76d143f81a9f
record_format	dspace
spelling	oai:doaj.org-article:ec98b4039ee4428da42d76d143f81a9f2021-12-02T16:28:06ZPopulation-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality10.1038/s41598-021-95764-32045-2322https://doaj.org/article/ec98b4039ee4428da42d76d143f81a9f2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95764-3https://doaj.org/toc/2045-2322Abstract We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large population-based dataset. 388,760 men who participated in national health screening program in Korea during 2002–2003 were observed from 2004 to 2013. Hazard ratios of aspirin, statins, and metformin use for PC incidence and PC mortality were calculated with adjustment for simultaneous drug use. Cumulative use of each drug was inserted as time-dependent variable with 2-year time windows. Aspirin use ≥ 1.5 year (per 2-year) was associated with borderline decrease in PC mortality when compared to non-users (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.50–1.02). Statins use was not associated with either PC incidence or PC mortality. Metformin ever-use was associated with decreased PC incidence compared with non-diabetics (aHR 0.86, 95% CI 0.77–0.96). Diabetics who were not using metformin or using low cumulative doses had higher PC mortality than non-diabetics (aHR 2.01, 95% CI 1.44–2.81, and aHR 1.70, 95% CI 1.07–2.69, respectively). However, subjects with higher cumulative doses of metformin did not show increased PC mortality. In conclusion, metformin use was associated with lower PC incidence. Use of aspirin and that of metformin among diabetic patients were associated with lower PC mortality.Hye Yeon KooSu-Min JeongMi Hee ChoSohyun ChunDong Wook ShinJinsung ParkNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hye Yeon Koo Su-Min Jeong Mi Hee Cho Sohyun Chun Dong Wook Shin Jinsung Park Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality
description	Abstract We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large population-based dataset. 388,760 men who participated in national health screening program in Korea during 2002–2003 were observed from 2004 to 2013. Hazard ratios of aspirin, statins, and metformin use for PC incidence and PC mortality were calculated with adjustment for simultaneous drug use. Cumulative use of each drug was inserted as time-dependent variable with 2-year time windows. Aspirin use ≥ 1.5 year (per 2-year) was associated with borderline decrease in PC mortality when compared to non-users (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.50–1.02). Statins use was not associated with either PC incidence or PC mortality. Metformin ever-use was associated with decreased PC incidence compared with non-diabetics (aHR 0.86, 95% CI 0.77–0.96). Diabetics who were not using metformin or using low cumulative doses had higher PC mortality than non-diabetics (aHR 2.01, 95% CI 1.44–2.81, and aHR 1.70, 95% CI 1.07–2.69, respectively). However, subjects with higher cumulative doses of metformin did not show increased PC mortality. In conclusion, metformin use was associated with lower PC incidence. Use of aspirin and that of metformin among diabetic patients were associated with lower PC mortality.
format	article
author	Hye Yeon Koo Su-Min Jeong Mi Hee Cho Sohyun Chun Dong Wook Shin Jinsung Park
author_facet	Hye Yeon Koo Su-Min Jeong Mi Hee Cho Sohyun Chun Dong Wook Shin Jinsung Park
author_sort	Hye Yeon Koo
title	Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality
title_short	Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality
title_full	Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality
title_fullStr	Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality
title_full_unstemmed	Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality
title_sort	population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ec98b4039ee4428da42d76d143f81a9f
work_keys_str_mv	AT hyeyeonkoo populationwideimpactsofaspirinstatinsandmetforminuseonprostatecancerincidenceandmortality AT suminjeong populationwideimpactsofaspirinstatinsandmetforminuseonprostatecancerincidenceandmortality AT miheecho populationwideimpactsofaspirinstatinsandmetforminuseonprostatecancerincidenceandmortality AT sohyunchun populationwideimpactsofaspirinstatinsandmetforminuseonprostatecancerincidenceandmortality AT dongwookshin populationwideimpactsofaspirinstatinsandmetforminuseonprostatecancerincidenceandmortality AT jinsungpark populationwideimpactsofaspirinstatinsandmetforminuseonprostatecancerincidenceandmortality
_version_	1718383966843568128

Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality

Ejemplares similares